Upcoming Events.
6TH Annual Digital Immuno-Oncology Innovation Forum
Immutep will participate to the virtual IOIF conference.
ASCO 2020 Virtual
Immutep will participate to the new virtual event format and will present:
“Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab”
BIO International Convention - Bio Digital
Immutep will participate to the new virtual event format.
Past Events.
ESMO Breast Cancer Congress 2020
Venue: Hub27 Berlin, Messedamm 22, 14055, Berlin, Germany
American Association for Cancer Research (AACR) Annual Meeting 2020
Venue: San Diego Convention Center, San Diego, California, USA
Immutep AIPAC Data Global Webcast (ASX:IMM; NASDAQ:IMMP)
Immutep will present this AIPAC data in a global webcast, details are as follows:
Date & Time: Thursday, March 26th, 8am Australian Eastern Daylight Time / Wednesday, March 25th, 5pm US Eastern Daylight Time
Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: http://public.viavid.com/index.php?id=138665
Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.
A replay of the webcast will also be available at www.immutep.com from the day after the event.
Click here for AIPAC Global Webcast Slides
Immutep Clinical Results Global Webcast (ASX:IMM; NASDAQ:IMMP)
The Company will present the interim TACTI-002 data and provide a further update on its clinical programs in a global webcast. The details for the webcast are as follows:
Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time
Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link:
https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f
Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.
A replay of the webcast will also be available at www.immutep.com from the day after the event.
38th Annual J.P. Morgan Health Care Investor Conference
BIO-Europe® - 25th Annual International Partnering Conference
Venue: CCH - Congress Center Hamburg, Am Dammtor / Marseiller Str., 20355 Hamburg, Germany
34th Annual Meeting SITC 2019
The company will have presentations at the conference and representatives will be attending.
Venue: Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA
https://www.nationalharbor.com/gaylord-national/
Click here for the "TACTI-002" poster which will be presented at the SITC 2019
AusBiotech Investment Events 2019
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Venue: Melbourne Convention & Exhibition Centre, Melbourne VIC 3006, Australia
World Immunotherapy Congress as part of Festival of Biologics 2019
Day 1 – Tuesday, 15th October/ 2.50 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology
Venue: Basel Congress Centre, Basel, Switzerland
ESMO 2019 Congress
Representatives of the company will be attending the conference.
Venue:
Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain
World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
Conference Day 2: Friday 17th May 2019/ 11.25.a.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials
Venue: Business Design Centre, London, UK
New York Academy of Sciences, Frontiers in Cancer Immunotherapy
Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.
Venue: The New York Academy of Sciences, New York, New York, USA
American Association for Cancer Research (AACR) Annual Meeting 2019
Venue: San Diego Convention Center, San Diego, California, USA
World Immunotherapy Congress USA 2019
Day 2 – Tuesday 5th March/ 3.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients
Venue: Grand Hyatt, San Diego, USA
37th Annual J.P. Morgan Health Care Investor Conference
Venue: San Francisco, California, USA
4th Annual ICI Europe Summit
conference day 1/ 02.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab
Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany
Macquarie Life Sciences Corporate Day - Sydney
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Macquarie Office - Sydney, Australia
33rd Annual Meeting SITC 2018
The company will have presentations at the conference and representatives will be attending.
Venue: Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA
World Immunotherapy Congress 2018
day 2/ 2:55 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab
Venue: Basel Congress Center, Basel, Switzerland
Australian Biotech Invest & Partnering 2018
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia
15th International Congress of the Society for Melanoma Research
Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:
"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."
Venue: Manchester Central Convention Complex, Manchester, United Kingdom
ESMO 2018 Congress
Representatives of the company will be attending the conference.
Venue: Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.
Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”
Download "Ladenburg 2018 HC Conference Immutep Presentation"
BioCentury 25th Annual NewsMakers - Biotech Industry Conference
Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day.
Venue: Millenium Broadway Hotel & Conference Center, NY, USA
Press release: click here
Download "Newsmaker Immutep Corporate Presentation"
Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018
BIONNALE 2018, Berlin, Germany
- the largest networking event for life sciences and healthcare industries in the German capital region -
Venue: Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
3rd Annual Advances in Immuno-Oncology Congress, 24 - 25 May 2018, London, UK
Frédéric Triebel speaks on the subject:
“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”
13th Annual Advanced Therapy and Regenerative Medicine Congress 2018, 16 – 18 May, London, UK
Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”
Deutsche Biotechnologietage 2018/ German Biotech Days 2018
Venue: bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany
American Association for Cancer Research (AACR) Annual Meeting 2018
Venue: McCormick Place, Chicago, IL, USA
The MicroCap Conference
Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th
Venue: Essex House, New York, NY, USA